250 mg/m2 aldoxorubicin

DRUG2 trials

Sponsors

ImmunityBio, Inc.

Conditions

GlioblastomaMetastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Phase 1

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

CompletedNCT02235701

ImmunityBio, Inc.Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma

Start: 2014-09-02End: 2018-05-01Updated: 2024-05-29

Phase 2

Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma

CompletedNCT02014844

ImmunityBio, Inc.Glioblastoma

Start: 2014-03-31End: 2016-12-31Updated: 2024-05-29

Related Papers

Administration of aldoxorubicin and 14 days continuous infusion of ifosfamide/mesna in metastatic or locally advanced sarcomas.

Journal of Clinical Oncology2017-05-206 citations

Phase 2 study of aldoxorubicin in relapsed glioblastoma.

Journal of Clinical Oncology2016-05-209 citations

A phase 1/2 study of continuous infusion ifosfamide/mesna + aldoxorubicin in sarcoma patients.

Journal of Clinical Oncology2016-05-203 citations